Moreover, an endothelin 1 genetic polymorphism as a predictive marker for bevacizumab in metastatic BC has been suggested: the single-nucleotide polymorphisms rs5370 in endothelin 1 could serve to identify patients who are unlikely to gain any advantage from bevacizumab [160]. Here, EDN1 is linked to breast cancer.